Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

1.750 +0.030 (+1.74%)
Streaming Delayed Price Updated: 12:41 PM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
A New Groundbreaking Tool to Detect Colon Cancer Earlier
A novel blood test for detecting colon cancer, the third most lethal type of cancer in the US, has been created. The Colorectal Cancer Screening Blood Test can identify cancer at early stages. This... 
Via PressReach
Colon Cancer Creeping Into Younger Adults – New R&D Uncovers Early Signs
Spots of blood after bowel movements, stomach aches, and protracted episodes of diarrhea may be symptoms of early-onset colorectal cancer, which is increasingly diagnosed in young adults who are... 
Via PressReach
Expert Ratings for Mainz Biomed
 
Via Benzinga
Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert
From Mainz BioMed NV
Via GlobeNewswire
AI Tool Predicts Colon Cancer Survivorship and Response to Treatment
Harvard Medical School and National Cheng Kung University in Taiwan have designed an artificial intelligence (AI) algorithm to improve colorectal cancer prognosis and treatment options. The new... 
Via PressReach
Topics Artificial Intelligence
New Artificial Intelligence Tool Can Diagnose Colon Cancer
A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and... 
Via PressReach
Topics Artificial Intelligence Death
Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed to Participate in Digestive Disease Week 2023
Largest international meeting of physicians, researchers, and academics covering gastroenterology, hepatology, endoscopy, and gastrointestinal surgery 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany
From Mainz BioMed NV
Via GlobeNewswire
Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its... 
Via Benzinga
Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal
The Instituto de Microecologia to market at-home detection test for colorectal cancer to physicians and their patients 
From Mainz BioMed NV
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's session saw 286 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During Friday's session, 149 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's trading, 123 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 99 companies made new 52-week lows. 
Via Benzinga
Mainz Biomed Provides Full Year 2022 Financial Results
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas
From Mainz BioMed NV
Via GlobeNewswire
Analysts Model Over 74% Upside For Mainz Biomed Stock Ahead Of Key 1/H 2023 Updates ($MYNZ)
Via AB Newswire
Mainz Biomed ($MYNZ) Inks Accretive Partnership To Expand Marketing Reach Of ColoAlert Diagnostic, Analysts Model For Over 72% Upside ($MYNZ)
Via AB Newswire
Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
Labor Staber to actively market and sell ColoAlert to its physician and patient network. 
From Mainz BioMed NV
Via GlobeNewswire
In Focus: Mainz Biomed Nears Multiple Data Set Releases Expected To Fuel 2023 Growth ($MYNZ)
Via AB Newswire
Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed In Focus Ahead Of Two Data-Set Releases In 1H/2023 ($MYNZ)
Via AB Newswire
Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023
Mainz Biomed to host several events for patients and healthcare professionals in Germany to increase awareness about the importance of early detection of colorectal cancer. 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed to Appear on ClearThink IR’s Virtual Live Event on Wednesday, March 1, 2023 at 12 Noon ET
Virtual Fireside Chat via Paltalk Platform 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed’s Milestones Reached In 2022 Can Be Catalysts In 1/H 2023…Here’s Why ($MYNZ)
Via AB Newswire
Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
From Mainz BioMed NV
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.